VEGFA and wet macular degeneration: Anti-vascular endothelial growth factor (VEGF) treatment with the monoclonal antibody brolucizumab (Beovu, Novartis) was launched in the USA in October 2019 as a novel treatment for neovascular age-related macular degeneration (AMD) [1,2].